BIOAI
LIVE

Serial Number

50061732

Owner

Earli Inc.

Attorney

Ted D. Karr

Filing Date

Aug 20, 2026

Add to watchlist:

No watchlists yet
View on USPTO

BIOAI Trademark

Serial Number: 50061732

BIOAI is a trademark filed by Earli Inc. on August 20, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Earli Inc. (10 trademarks)

Mountain View, CA 94022

Entity Type: 03

Trademark Details

Filing Date

August 20, 2026

Registration Date

Not Registered

Goods & Services

Products for the prevention of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the detection of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the localization of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for localization of cancer; Products for the therapy of cancer in humans, namely, pharmaceutical products to express a treatment agent for treating cancer; Products for the prevention of cancer in animals, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the detection of cancer in animals, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the therapy of cancer in animals, namely, pharmaceutical products to express a treatment agent for treating cancer

Medical services for the prevention of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for detecting cancer; Medical services for the detection of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for detection of cancer; Medical services for the localization of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for the localization of cancer; Medical services for the therapy of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for treating cancer; Medical services for the prevention of cancer in animals, namely, medical assay processing provided by medical laboratories and medical analysis services for detecting cancer; Medical services for the detection of cancer in animals, namely, medical assay processing provided by medical laboratories and medical analysis services for detection of cancer; Medical services for the therapy of cancer in animals, namely, medical assay processing provided by medical laboratories and medical analysis services for the treatment of cancer

Filing History

APPLICATION FILING RECEIPT MAILED
Aug 20, 2026 MAFR
NEW APPLICATION ENTERED
Aug 20, 2026 NWAP